A new drug has been found to reduce the risk of cancer reoccurring by 50 percent and a Richmond hospital is
behind a major medical breakthrough for breast cancer patients.
Read more: : https://www.mystateline.com/news/researchers-testing-drug-that-reduces-breast-cancer-by-50-percent/1712197030
There are around 7,000 rare or ‘orphan’ diseases for which there currently exists no authorized or satisfactory
method of treatment. Many are life-threatening or debilitating, and they particularly affect the very young, who
often do not survive beyond adolescence.
Read more at: http://www.pharmatimes.com/web_exclusives/orphan_drug_development_and_the_urgent_need_for_a_new_approach_1271944
Two years later, when you ask pharma people for their overarching thoughts about their fate so far under
President Donald Trump, their responses are peppered with disbelieving giggles
Read more : https://www.mmm-online.com/home/channel/regulatory/how-the-pharma-industry-may-be-impacted-by-drug-pricing-and-other-policies-in-2019/
PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities (NCEs), generic active
pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that
will affect the emerging biotech and generic drug sectors
Read more at: https://www.rdmag.com/news/2018/12/cdmo-identifies-trends-affecting-generic-drugs-sector-2019
Biopharma industry watchers, executives, and especially investors often display that same desire as a year comes
to a close, which explains why there’s typically a wave of news articles and commentaries attempting to divine
events of the coming year based on the 12 months that are coming to a close.
Read more at: https://www.genengnews.com/lists/5-biopharma-trends-to-watch-in-2019/